News Novartis/Amgen migraine drug shows promise Mid-stage data suggests drug reduces monthly migraine days.
News Novartis Breezhaler bests GSK's Seretide in COPD Ultibro showed consistent reductions in rate of all exacerbations, whether mild, moderate, or severe.
Views & Analysis Novartis committed to CAR-Ts - but doubts about commercial v... Novartis may have concerns about commercial prospects, says expert.
News Novartis move damages CAR-T confidence Swiss pharma axes gene therapy unit, causing investor angst.
News Novartis' Arzerra gains CLL approval Development partner Genmab says drug approved in relapsed disease.
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
